Company registration number 10098728 (England and Wales)
CONNECT PHARMA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025
PAGES FOR FILING WITH REGISTRAR
CONNECT PHARMA LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
CONNECT PHARMA LIMITED
BALANCE SHEET
AS AT
31 MAY 2025
31 May 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
240,086
121,006
Current assets
Debtors
4
2,471,850
708,059
Cash at bank and in hand
724,230
1,568,559
3,196,080
2,276,618
Creditors: amounts falling due within one year
5
(820,218)
(253,596)
Net current assets
2,375,862
2,023,022
Total assets less current liabilities
2,615,948
2,144,028
Creditors: amounts falling due after more than one year
6
(107,121)
(104,673)
Provisions for liabilities
Deferred taxation
(17,528)
(30,251)
Net assets
2,491,299
2,009,104
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
2,491,199
2,009,004
Total equity
2,491,299
2,009,104

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

CONNECT PHARMA LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MAY 2025
31 May 2025
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 26 May 2026 and are signed on its behalf by:
Mr J Cattee
Director
Company registration number 10098728 (England and Wales)
CONNECT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025
- 3 -
1
Accounting policies
Company information

Connect Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is 11 Manchester Road, Walkden, Manchester, United Kingdom, M28 3NS.

The principal place of business is Buttermilk Lane, Bolsover, Chesterfield, United Kingdom, S44 6AE.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover comprises the fair value of the sale of goods and services net of value added tax, returns, rebates and discounts. Sales of goods and services are recognised either at the point of sale or when the company has delivered them to the customer.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Office equipment
10% straight line
Computer equipment
33% straight line
Motor vehicles
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

CONNECT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
1
Accounting policies
(Continued)
- 4 -
Deferred tax

Deferred tax is recognised on all timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

1.5
Leases

Assets held under hire purchase contracts are capitalised in the balance sheet and are depreciated over their useful lives. The capital of future obligations under hire purchase contracts are included in liabilities in the balance sheet.

The interest element of the rental obligations are charged to the profit and loss account over the period of the hire purchase contract.

Rentals payable under operating leases are charged in the profit and loss account over the lease term.

1.6

Pensions

The obligations for contributions to a defined contribution scheme are recognised as an expense in the period in which they are incurred. The assets of the scheme are held separately from those of the company in an independently administered fund.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
4
4
CONNECT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
- 5 -
3
Tangible fixed assets
Office equipment
Computer equipment
Motor vehicles
Total
£
£
£
£
Cost
At 1 June 2024
6,417
3,093
146,492
156,002
Additions
1,131
799
180,824
182,754
Disposals
-
0
-
0
(66,667)
(66,667)
At 31 May 2025
7,548
3,892
260,649
272,089
Depreciation and impairment
At 1 June 2024
185
2,319
32,492
34,996
Depreciation charged in the year
755
547
24,871
26,173
Eliminated in respect of disposals
-
0
-
0
(29,166)
(29,166)
At 31 May 2025
940
2,866
28,197
32,003
Carrying amount
At 31 May 2025
6,608
1,026
232,452
240,086
At 31 May 2024
6,232
774
114,000
121,006
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
889,143
183,825
Other debtors
1,582,707
524,234
2,471,850
708,059
5
Creditors: amounts falling due within one year
2025
2024
£
£
Obligations under finance leases
16,926
12,119
Trade creditors
99,343
4,081
Corporation tax
277,075
228,440
Other taxation and social security
416,263
-
0
Other creditors
10,611
8,956
820,218
253,596

Creditors include net obligations under finance lease and hire purchase contracts which are secured of £16,926 (2024 - £12,119).

CONNECT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
- 6 -
6
Creditors: amounts falling due after more than one year
2025
2024
£
£
Obligations under finance leases and hire purchase contracts
107,121
104,673

Creditors include net obligations under finance lease and hire purchase contracts which are secured of £107,121 (2024 - £104,673).

7
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
5,513
10,052
8
Related party transactions
Transactions with related parties

During the year, the company advanced loans of £912,250 to Peak Evolution Limited and £60,000 to Cattee Investments Limited, that is included in debtors.

During the previous year, the company advanced a loan of £500,000 to Cattee Investments Limited, that is included in debtors. Mr. J Cattee is a shareholder and director of these companies.

2025-05-31 2024-06-01 false false false 26 May 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mrs A Bailey Mr J Cattee Mr L Goodman 10098728 2024-06-01 2025-05-31 10098728 2025-05-31 10098728 2024-05-31 10098728 core:FurnitureFittings 2025-05-31 10098728 core:ComputerEquipment 2025-05-31 10098728 core:MotorVehicles 2025-05-31 10098728 core:FurnitureFittings 2024-05-31 10098728 core:ComputerEquipment 2024-05-31 10098728 core:MotorVehicles 2024-05-31 10098728 core:CurrentFinancialInstruments core:WithinOneYear 2025-05-31 10098728 core:CurrentFinancialInstruments core:WithinOneYear 2024-05-31 10098728 core:Non-currentFinancialInstruments core:AfterOneYear 2025-05-31 10098728 core:Non-currentFinancialInstruments core:AfterOneYear 2024-05-31 10098728 core:ShareCapital 2025-05-31 10098728 core:ShareCapital 2024-05-31 10098728 core:RetainedEarningsAccumulatedLosses 2025-05-31 10098728 core:RetainedEarningsAccumulatedLosses 2024-05-31 10098728 bus:Director2 2024-06-01 2025-05-31 10098728 core:FurnitureFittings 2024-06-01 2025-05-31 10098728 core:ComputerEquipment 2024-06-01 2025-05-31 10098728 core:MotorVehicles 2024-06-01 2025-05-31 10098728 2023-06-01 2024-05-31 10098728 core:FurnitureFittings 2024-05-31 10098728 core:ComputerEquipment 2024-05-31 10098728 core:MotorVehicles 2024-05-31 10098728 2024-05-31 10098728 core:CurrentFinancialInstruments 2025-05-31 10098728 core:CurrentFinancialInstruments 2024-05-31 10098728 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 10098728 bus:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 10098728 bus:FRS102 2024-06-01 2025-05-31 10098728 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 10098728 bus:Director1 2024-06-01 2025-05-31 10098728 bus:Director3 2024-06-01 2025-05-31 10098728 bus:FullAccounts 2024-06-01 2025-05-31 xbrli:pure xbrli:shares iso4217:GBP